Revumenib
Syndax Pharma
['revumenib', 'augment,trial', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'augment-101', 'leukemia']
ghayas c. issa, md presents the plans for a phase 2 augment-101 trial of revumenib, the successful menin-kmt2a inhibitor, to treat acute leukemia with kmt2ar (mllr) or mnpm1. #ash22 #amlsm #aml 
HealthTree for AML is a united community of AML patients, caregivers & medical professionals that provides support, education & tools to accelerate a cure